Oruka Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Oruka Therapeutics, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-142.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 88% of Healthcare companies in United States.
Cash Cushion Ratio
+6%Cash, after subtracting all debt, equals 6% of its market value (net cash).
Lower than 55% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Oruka Therapeutics, Inc. made a loss over the last year. Oruka Therapeutics, Inc. owes $0.02 for every $1 it owns.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOruka Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
4.83The share price is 4.83 times Oruka Therapeutics, Inc.'s book value per share, higher than 71% of Healthcare companies in United States.
Market cap
$5.4 BThe total market value of all of Oruka Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 85% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.1 BWhat Oruka Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$16.79Net worth divided by the number of shares. The share price of $81.15 is 4.8 times this, which is the P/B above.
Return on equity (ROE)
-18.2%Oruka Therapeutics, Inc. lost 18.2% of its shareholders' money over the last year, higher than 66% of Healthcare companies in United States.
Owes vs Owns
0.02×Oruka Therapeutics, Inc. owes $0.02 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Dividend yield
NoneOruka Therapeutics, Inc. does not currently pay a dividend.
Cash vs debt
Net cashOruka Therapeutics, Inc. held $335 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Oruka Therapeutics, Inc.: $5.4 B ÷ $1.1 B (30 Jun 2026) = 4.8.
What is Oruka Therapeutics, Inc.'s return on equity?
Oruka Therapeutics, Inc. lost 18.2% of its shareholders' money over the last year, higher than 66% of Healthcare companies in United States.
How much does Oruka Therapeutics, Inc. owe compared with what it owns?
Oruka Therapeutics, Inc. owes $0.02 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Does Oruka Therapeutics, Inc. pay a dividend?
No. Oruka Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.